Your session is about to expire
← Back to Search
Brain Stimulation
Brain Stimulation for Schizophrenia
N/A
Waitlist Available
Led By Tarek K Rajji, MD
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day and 7 days post n-back task
Awards & highlights
Study Summary
This triallooks at how a drug can improve memory and brain activity in people with schizophrenia.
Who is the study for?
This trial is for adults diagnosed with schizophrenia or schizoaffective disorder, stable in their condition and medication. They must be able to understand English, provide consent, and have adequate vision and hearing. Excluded are those with bipolar disorder, major depression, recent drug dependence, certain psychiatric diagnoses, a family history of psychosis in close relatives, unstable psychotropic medication use, left-handedness or other neurological issues.Check my eligibility
What is being tested?
The study tests the effects of brain stimulation (Transcranial Magnetic Stimulation) on the dorsolateral prefrontal cortex in schizophrenia patients. It aims to see if this can improve cognitive tasks related to that brain area by inducing long-term potentiation (LTP), which is like strengthening brain connections.See study design
What are the potential side effects?
While not specified here, Transcranial Magnetic Stimulation may cause discomfort at the stimulation site on the scalp, headache or lightheadedness during or after treatment. In rare cases it could induce seizures.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 day and 7 days post n-back task
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day and 7 days post n-back task
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Changes in working memory
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: PAS 25Active Control1 Intervention
In humans, paired associative stimulation (PAS-25) is a transcranial magnetic stimulation (TMS) protocol that has been shown to result in LTP-like plasticity (PAS-LTP) in the motor cortex (M1). PAS-LTP has been shown to be dependent on the NMDAR and to correlate significantly with performance on a motor learning task.
Group II: PAS 100Placebo Group1 Intervention
To control for non-specific effects of PAS protocol, the investigators will use a modified PAS protocol (PAS-100) that does not result in any neurophysiologic effects. Patients with schizophrenia and healthy controls will be assessed first with the N-back task and then randomized
Find a Location
Who is running the clinical trial?
National Alliance for Research on Schizophrenia and DepressionOTHER
96 Previous Clinical Trials
4,057 Total Patients Enrolled
37 Trials studying Schizophrenia
1,931 Patients Enrolled for Schizophrenia
Centre for Addiction and Mental HealthLead Sponsor
354 Previous Clinical Trials
81,048 Total Patients Enrolled
58 Trials studying Schizophrenia
4,159 Patients Enrolled for Schizophrenia
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,340 Previous Clinical Trials
26,452,626 Total Patients Enrolled
13 Trials studying Schizophrenia
727,500 Patients Enrolled for Schizophrenia
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- People of all races and ethnicities are eligible.You currently have a diagnosis of schizophrenia or schizoaffective disorder according to the DSM-IV TR criteria.I haven't been hospitalized recently and my medication dose hasn't changed in the last month.You can see well enough to read a newspaper headline with the help of glasses or contacts, and you can hear well enough to respond to someone speaking in a slightly raised voice.I have been on a stable dose of my psychotropic medication for at least 4 weeks.A close family member has had a severe mental health disorder.I am either male or female.I have not had electroconvulsive therapy in the last 6 months.I have a cognitive disorder due to a condition like MS, brain injury, stroke, or untreated thyroid issues.I have a brain or nerve condition.I am 18 years old or older.I have been diagnosed with bipolar disorder or am currently experiencing a major depressive episode.I am unable to understand and give consent for treatment.You are left-handed.I can and am willing to communicate in English.
Research Study Groups:
This trial has the following groups:- Group 1: PAS 25
- Group 2: PAS 100
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are adolescents within the age range of eligibility for this trial?
"In line with the study's inclusion parameters, only individuals aged 18 to 60 can be enrolled in this clinical trial."
Answered by AI
Would I be eligible to participate in this research experiment?
"To be considered for this trial, applicants must have schizophrenia and fall between the ages of 18-60. 72 individuals will ultimately join the study."
Answered by AI
Is this research program actively recruiting participants?
"This trial, which was first released on March 1st 2012 and last changed February 8th 2023, is no longer in need of participants. However, clinicaltrials.gov lists 332 other trials actively recruiting patients at this time."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger